Radioligand therapy with drugs based on radionuclide 225Aс: experience of A.M.Granov Russian scientific center of radiology and surgical technologies
https://doi.org/10.22328/2079-5343-2022-13-4-86-94
Abstract
INTRODUCTION: Peptide receptor therapy based on the 225Ac radionuclide, due to the targeted effect on tumor cells, is the most promising method of treatment for patients with generalized forms of neuroendocrine tumors and castration-resistant prostate cancer.
OBJECTIVE: The aim of the work was to evaluate the effectiveness of radioligand therapy of medicinal radiopharmaceuticals with 225Ac.
MATERIALS AND METHODS: Radioligand therapy based on 225Ac radionuclide was performed in 7 patients with generalized prostate cancer and 3 patients with neuroendocrine tumors.
RESULTS: Systemic radiation therapy with 225Ac-PSMA 617 and 225Ac-DOTATE showed its effectiveness in clinical practice — patients have a decrease in the level of accumulation of the radiopharmaceutical (RP) in pathological foci on PET-CT with 68Ga-PSMA and 68Ga-DOTATE; a decrease in the level of prostate-specific antigen (PSA) in the blood (for prostate cancer); reduction of manifestations of asthenic, pain and carcinoid (for neuroendocrine tumors) syndromes. Dosimetric studies make it possible to assess the biodistribution of a radiopharmaceutical drug in the body, accumulation in target organs and lesions.
CONCLUSION: The appointment of this type of treatment requires an integrated approach based on a thorough study of medical records, assessment of the receptor status of the tumor tissue, timely detection and prediction of adverse reactions.
About the Authors
D. N. MaystrenkoRussian Federation
Dmitry N. Maystrenko — Dr. of Sci (Med.), Head
SPIN 7363–4840
St. Petersburg. Pos. Pesochny, Leningradskaya street 70
A. A. Stanzhevskii
Russian Federation
Andrei A. Stanzhevskii — Dr. of Sci (Med.), Deputy Director for Research
SPIN 4025–4260
St. Petersburg. Pos. Pesochny, Leningradskaya street 70
D. A. Vazhenina
Russian Federation
Daria A. Vazhenina — Dr. of Sci (Med.), Radiologist Laboratory of Isotope Research Methods, Chief Researcher
SPIN 2411–6704
St. Petersburg. Pos. Pesochny, Leningradskaya street 70
M. V. Odintsova
Russian Federation
Maria V. Odintsova — Cand. of Sci. (Med.), Head of radiotherapy department No. 1 (day hospital) with the radionuclide therapy group
St. Petersburg. Pos. Pesochny, Leningradskaya street 70
S. A. Popov
Russian Federation
Sergey A. Popov — Cand. of Sci. (Med.), Head of the Department of Abdominal Oncology and X-Ray Surgical Methods of Diagnosis and Treatment
SPIN 2615–8848
St. Petersburg. Pos. Pesochny, Leningradskaya street 70
V. B. Nomokonova
Russian Federation
Valeria B. Nomokonova — oncologist of the radiotherapy department No 1 (day hospital) with the radionuclide therapy group
SPIN 3614–6669
St. Petersburg, Pos. Pesochny, Leningradskaya street 70
L. A. Chipiga
Russian Federation
Larisa A. Chipiga — Cand. of Sci. (Med.), research fellow, Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V.Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being; research fellow, A.M.Granov Russian Scientific Center of Radiology and Surgical Technologies of the Ministry of Health of the Russian Federation; docent, Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation
SPIN 3920–7798
St. Petersburg, st. Mira, 8;
St. Petersburg, Pos. Pesochny, Leningradskaya street 70
K. A. Saprykin
Russian Federation
Kirill A. Saprykin — Senior Researcher Head of the Laboratory for Dosimetry of Natural Sources Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V.Ramzaev Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being
SPIN 1950–9242
St. Petersburg, st. Mira, 8
A. V. Gromov
Russian Federation
Alexey V. Gromov — Cand. of Sci. (Med.), Senior Researcher, head of emergency response laboratory Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V.Ramzaev Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being
SPIN 7536–0928
St. Petersburg, st. Mira, 8
S. K. Vasiliev
Russian Federation
Sergey K. Vasiliev — Ph.D. Leading Researcher Radium Institute named after V.G. Khlopin JOINT-STOCK COMPANY
St. Petersburg, 2nd Murinsky Ave, 28
References
1. Morgenstern A. An Overview of Targeted Alpha Therapy with 225 Actinium and 213 Bismuth // Current Radiopharmaceuticals. 2018. Vol. 11, No. 3, pp. 200–208. doi: 10.2174/1874471011666180502104524.
2. Kratochwil C. Targeted a-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225 Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding // The Journal of Nuclear Medicine. 2017. Vol. 58, No. 10, pp. 1624–1631. doi: 10.2967/jnumed.117.191395.
3. Özgüven S. Physiological Biodistribution of 68 Ga-DOTA-TATE in Normal Subjects // Molecular Imaging And Radionuclide Therapy. 2021. Vol. 30, No. 1, pp. 39–46. doi: 10.4274/mirt.galenos.2021.37268.
4. Hooijman E. Development of [ 225 Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC // Pharmaceutic. 2021. Vol. 13, No. 5. Р. 715. doi: 10.3390/pharmaceutics13050715.
5. Birindelli G. In silico study on radiobiological efficacy of Ac-225 and Lu-177 for PSMA-guided radiotherapy // 43 rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society (USA, New York, 01–05 November 2021 year). New York, 2021. Р. 4497–4500. doi: 10.1109/EMBC46164.2021.9630297.
6. Lunger L. Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer // Translational Andrology and Urology. 2021. Vol. 10, No. 10. Р. 3963–3971. doi: 10.21037/tau-20-1135.4.
7. Stefe M. Intra-therapeutic dosimetry of [ 177 Lu] Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome // European Journal of Nuclear Medicine and Molecular Imaging. 2022. Vol. 49, No. 2. Р. 460–469. doi: 10.1007/s00259-021-05471-4.
8. Шкала ECOG. https://onconet.online/lib/4/diagn/207 (дата обращения 18.11.2022).
9. Критерии PERCIST. https://recist.eortc.org/recist-1–1-2 (дата обращения 18.11.2022).
10. Radionuklidnaya diagnostika dlya prakticheskikh vrachey / pod redaktsiyey Lishmanova Yu.B., Chernova V.I., Novosibirsk: STT, 2004. 387 s. [Radionuclide diagnostics for practitioners / ed. by Yu.B.Lishmanov, V.I.Chernov. Novosibirsk: STT Publishing house, 2004. 387 p. (In Russ.)].
11. Afanas’yev V.V. Slyunnyye zhelezy. Bolezni i travmy: rukovodstvo dlya vrachey. Moskva: GEOTAR-Media, 2012. 296 s. [Afanasiev V.V. Salivary glands. Diseases and injuries: a guide for doctors. Moscow: Publishing house GEOTAR-Media, 2012. 296 p. (In Russ.)].
Review
For citations:
Maystrenko D.N., Stanzhevskii A.A., Vazhenina D.A., Odintsova M.V., Popov S.A., Nomokonova V.B., Chipiga L.A., Saprykin K.A., Gromov A.V., Vasiliev S.K. Radioligand therapy with drugs based on radionuclide 225Aс: experience of A.M.Granov Russian scientific center of radiology and surgical technologies. Diagnostic radiology and radiotherapy. 2022;13(4):86-94. (In Russ.) https://doi.org/10.22328/2079-5343-2022-13-4-86-94